A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

HIV Infections Clinical Trial

Official title:

A 2-part, Phase 1, Single-center, Open-label Study to Assess the Relative Bioavailability of Oral Formulations for an Investigational Capsid Inhibitor in Healthy Adult Participants, and to Evaluate the Effect of Food on Bioavailability for an Investigational Capsid Inhibitor in Healthy Adult Participants

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06168318
• Other study ID #: 220095
• Status: Recruiting
• Phase: Phase 1
• Start date: December 18, 2023
• Est. completion date: June 18, 2024

Study information

• Verified date: January 2024
• Source: ViiV Healthcare
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2 part study of an investigational capsid inhibitor, VH4004280, in healthy adult participants. The purpose is to evaluate the effect of tablet formulation as well as food on bioavailability. Part 1 of the study will compare the relative bioavailability of VH4004280 Formulation A tablets to up to 4 alternative tablet formulations under fed (high fat) conditions. Part 2 of the study will assess the effect of fasted conditions on the bioavailability of VH4004280 Formulation A and alternative, optional formulations, relative to their respective bioavailability under fed conditions in Part 1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: June 18, 2024
• Est. primary completion date: June 18, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Participants who are overtly healthy.

2. Negative (Severe Acute Respiratory Syndrome Coronavirus 2) SARs-CoV-2 test prior to dosing.

3. Has body mass index (BMI) within the range 19-32 (kg/m2).

4. Participants male at birth must use male condoms, and participants female at birth who are of childbearing potential must be using acceptable forms of birth control.

5. Capable of giving signed informed consent.

Exclusion Criteria:

1. History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs.

2. Abnormal blood pressure.

3. Any malignancy within the past 5 years except certain localized malignancies, or breast cancer within the past 10 years.

4. Has exclusionary psychiatric, hepatic, cardiovascular, gastrointestinal, respiratory, endocrine, neurological, hematological, or renal condition.

5. Current or chronic history of liver disease or known hepatic or biliary abnormalities.

6. Participants with exclusionary electrocardiogram findings.

7. Past or intended use of exclusionary medications or vaccines.

8. Exposure > 4 new investigational products within 12 months, previous participation in this study, or current enrolment or participation in another investigational study.

9. ALT >1.5x upper limit of normal (ULN), total bilirubin >1.5x ULN, and/or estimated serum creatinine clearance <60 mL/min.

10. History of or current infection with hepatitis B or hepatitis C.

11. Positive SARS-CoV-2 test, having signs and symptoms suggestive of COVID-19, or contact with known COVID-19 positive person.

12. Positive HIV antibody test.

13. Participants with positive results for illicit drug use, regular use of drugs of abuse, tobacco or nicotine-containing product use, and/or excessive alcohol use.

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• VH4004280 Formulation A
Oral administration of VH4004280 Formulation A in fasted or fed conditions.
• VH4004280 Formulation B
Oral administration of VH4004280 Formulation B in fasted or fed conditions.
• VH4004280 Formulation C
Oral administration of VH4004280 Formulation C in fasted or fed conditions.
• VH4004280 Formulation D
Oral administration of VH4004280 Formulation D in fasted or fed conditions.
• VH4004280 Formulation E
Oral administration of VH4004280 Formulation E in fasted or fed conditions.

Locations

Country	Name	City	State
United Kingdom	GSK Investigational Site	Ruddington Fields	Nottinghamshire

Sponsors (1)

Lead Sponsor	Collaborator
ViiV Healthcare

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration - time curve from time zero (pre-dose) to infinity time (AUC[0-inf]) of VH4004280 in fed conditions		From Day 1 to Day 49
Primary	Area under the plasma drug concentration - time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tlast) of VH4004280 in fed conditions		From Day 1 to Day 49
Primary	Maximum observed plasma drug concentration (Cmax) of VH4004280 in fed conditions		From Day 1 to Day 49
Primary	Time to maximum observed plasma concentration (Tmax) of VH4004280 in fed conditions		From Day 1 to Day 49
Secondary	Number of participants with AEs (Adverse Events), by severity	An AE is any untoward medical occurrence in a participant or clinical investigation participant and can be any sign, symptom, or disease temporally associated with the use of a medicinal product. The severity scale is assessed as following: Grade 1 = mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated. Grade 2 = moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated. Grade 3 = severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated. Grade 4 = potentially life-threatening symptoms causing inability to perform self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.	From Day 1 to Day 49
Secondary	Number of participants with maximum toxicity grade increase from baseline for liver laboratory parameters	The assessed laboratory assessments include Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline phosphatase (ALP), direct bilirubin and total bilirubin, in both fed and fasted conditions.	From Day 1 to Day 49
Secondary	Change from baseline in liver panel parameters: Total bilirubin and direct bilirubin (micromoles per liter)		From Day 1 to Day 49
Secondary	Change from baseline in liver panel parameters: ALT, ALP and AST (International units per liter)		From Day 1 to Day 49